We have recently identified the interaction between the NF-kB-regulated antiapoptotic factor, GADD45β, and the JNK kinase, MKK7, as a therapeutic target in multiple myeloma (MM), an incurable plasma cell malignancy accounting for about 2% of all cancer deaths and representing a paradigm for NF-kB-driven cancers [2,5]. The gene discussed is MAP2K7; the disease is plasma cell myeloma.